And another achievement, enhancing medicines accessibility!

A.forall, is proud to announce that its U.S. partner, Woodward Pharma Services LLC, has just commercialized its Supplemental Abbreviated New Drug Application (sANDA) approval from the U.S. Food and Drug Administration (FDA) for a generic version of Sodium Acetate Injection 4 mEq/mL marketed by Fresenius Kabi USA LLC.

Sodium Acetate Injection, 2 mEq/mL has been commercialized since July 2021 and this newly launched 4 mEq/mL is a more concentrated version that is  used to supply sodium in large intravenous (IV) fluids for patients who can’t take fluids by mouth. It’s also an ingredient in custom IV fluid mixes when standard solutions aren’t suitable for specific patient’ needs.

This new concentration complements A.forall’s commitment to making affordable medicines available to all.

Filip Van de Vliet, CEO of A.forall, emphasized, “Our joint mission of making affordable medicines available to all is more than ever at the centre of what we do every day.”

You can find our full statement in our press release, here: Link.